TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer Cells New Monotherapy Approved for Use in a Cancer with Limited Treatment Options ...
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (GMAB) (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK ® (tisotumab vedotin), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results